Home Depot's CEO says the retailer cut its outlook partly due to "the potential impacts to the U.S. consumer arising from recently announced tariffs."Retailread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
While the U.S. gave Huawei a 90-day reprieve, allowing American businesses to keep selling specific products to the Chinese firm, it also added more affiliates of the...Technologyread more
The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
GE kicks off a new week after some crazy moves. Two traders urge caution.Trading Nationread more
Porsche and Apple believe music streaming is the next advancement for in-car entertainment. The luxury automaker and tech giant are teaming up to allow drivers of the all-new,...US: Consumer Servicesread more
J.P. Morgan advised clients in a note early Tuesday that it was time to buy shares of Beyond Meat again.Marketsread more
U.K. Prime Minister Boris Johnson told the EU that a Brexit deal can still be approved by U.K. lawmakers if Brussels agrees to scrapping the contentious Irish "backstop."read more
Baidu posted better-than-expected earnings for the June quarter, swinging back to profit and managing to stabilize its core ad business.Technologyread more
An exchange-traded fund based in mortgage-backed securities may provide just the kind of stable income investors need in this market, says ETF.com's Dave Nadig.ETF Edgeread more
Pharmaceutical companies have to start thinking about partnering with cannabis companies as a "hedge" against the burgeoning marijuana industry, Brendan Kennedy, the CEO of medical cannabis producer Tilray, said Tuesday on CNBC.
"They have to hedge this," Kennedy told "Mad Money " host in an exclusive interview. "Cannabis is a substitute for prescription painkillers, prescription opioids, and so if you're an investor in a pharmaceutical company or you're a pharmaceutical company, you have to hedge the offset from cannabis substitution."
The CEO said the same goes for alcohol producers, some of which, namely Constellation Brands, have already begun to invest heavily in marijuana companies.
"I think all the alcohol companies need to enter this industry. It's a great hedge for them," Kennedy told Cramer. "Whether you're an alcohol company or an investor in an alcohol company, this is a global opportunity."
In March, Tilray formed a "strategic alliance" with a division of Novartis called Sandoz, which specializes in generic pharmaceuticals, to help the Swiss drugmaker build this kind of hedge. In return, Novartis will help Tilray co-market and co-develop its products.
But if partnership interest were to arise from companies like Anheuser-Busch InBev, the maker of Budweiser, Kennedy wasn't too keen on its potential.
"We don't want to partner with ABI. We want to build ABI," he said. "Our intent is to build a company that dominates part of this $150 billion industry. I think you'll see multiple hundred-billion-dollar companies."
There are currently no talks between the companies.
On Tuesday, shares of Tilray surged 29 percent to a new 52-week high after the U.S. Drug Enforcement Administration said it would allow the Canada-based marijuana cultivator to ship its product to the United States for medical research.
Yet, even with full legalization coming to Canada in October, Kennedy was focused on the bigger picture.
"There's a clear global growth opportunity when it comes to medical cannabis," he said. "With Canada, we're about to see 100 percent growth: one country, Uruguay, to two countries, Canada. What intrigues me is country three, four, five and six. "
And the rest won't take long, the CEO said.
"I think you'll see the third country within 12 months of October, and that's where the real opportunity is," he told Cramer. "It's not about Canada, it's about all the countries that follow."
Shares of Tilray are up more than 500 percent since the company's U.S. trading debut in July. The stock ended Tuesday's trading session at $154.98 a share, up 28.95 percent.
Correction: Tilray's stock has risen more than 500 percent since the company's U.S. trading debut in July. An earlier version misstated the percentage.